These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 21613622)

  • 1. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
    Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
    Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
    Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
    J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
    Boddapati S; Levites Y; Sierks MR
    J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
    Sun X; Wang Y; Qing H; Christensen MA; Liu Y; Zhou W; Tong Y; Xiao C; Huang Y; Zhang S; Liu X; Song W
    FASEB J; 2005 May; 19(7):739-49. PubMed ID: 15857888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
    Stockley JH; O'Neill C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
    Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
    Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Barnes K; Hui Y; Johnson M; Lovering F; Condon J; Fobare W; Solvibile W; Turner J; Hu Y; Manas ES; Fan K; Olland A; Chopra R; Bard J; Pangalos MN; Reinhart P; Robichaud AJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2068-73. PubMed ID: 20223661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
    Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
    J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
    Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
    J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta'-cleavage sites by human and murine BACE1.
    Yang HC; Chai X; Mosior M; Kohn W; Boggs LN; Erickson JA; McClure DB; Yeh WK; Zhang L; Gonzalez-DeWhitt P; Mayer JP; Martin JA; Hu J; Chen SH; Bueno AB; Little SP; McCarthy JR; May PC
    J Neurochem; 2004 Dec; 91(6):1249-59. PubMed ID: 15584902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
    Sun X; He G; Song W
    FASEB J; 2006 Jul; 20(9):1369-76. PubMed ID: 16816112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.